IMVT Immunovant Inc.

13.44
+0.57  (+4%)
Previous Close 12.87
Open 12.63
Price To Book
Market Cap 758,760,253
Shares 56,455,376
Volume 115,149
Short Ratio
Av. Daily Volume 120,665
Stock charts supplied by TradingView

NewsSee all news

  1. Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

    Norwood, MA, March 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target

  2. Orchestra BioMed™ Adds Seasoned Biotech Executive Pamela Yanchik Connealy to Board of Directors

    Ms. Yanchik Connealy will serve as the Audit Committee Chair, strengthening Orchestra BioMed's financial reporting capabilities NEW HOPE, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. ("Orchestra

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a initial data due 4Q 2020.
IMVT-1401
Warm autoimmune hemolytic anemia
Phase 2 top-line data due 1H 2020.
IMVT-1401
Myasthenia Gravis (MG)
Phase 2a initial data due 1Q 2020.
IMVT-1401
Graves Ophthalmopathy
Phase 2b top-line data due early 2021.
IMVT-1401
Graves Ophthalmopathy

Latest News

  1. Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director

    Norwood, MA, March 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target

  2. Orchestra BioMed™ Adds Seasoned Biotech Executive Pamela Yanchik Connealy to Board of Directors

    Ms. Yanchik Connealy will serve as the Audit Committee Chair, strengthening Orchestra BioMed's financial reporting capabilities NEW HOPE, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc. ("Orchestra